SCHEMBL6797910

SCHEMBL6797910

Cn1c(C(=O)NC(=N)N)cc2cccc(OS(=O)(=O)O)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.35
FABP1 P07148 1/20 0.34
LMNA P02545 5/20 0.33
TP53 P04637 4/20 0.33
MAPT P10636 1/20 0.33
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
GALR3 O60755 1/20 0.32
GAA P10253 1/20 0.32
PHGDH O43175 1/20 0.31
SLC9A1 P19634 1/20 0.31
KDM4E B2RXH2 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HDAC1 Q13547 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797917 0.89 MCL1 (0.34) MCL1LMNATP53MAPTGALR3
SCHEMBL6795754 0.84 KMT2A (0.34) LMNATP53MAPTITGB3ITGA2B
SCHEMBL6796151 0.82 SLC9A1 (0.39) MCL1LMNATP53MAPTGALR3
SCHEMBL6799899 0.80 KDM4E (0.35) LMNATP53MAPTPHGDHKDM4E
SCHEMBL6796789 0.78 KMT2A (0.32) LMNATP53MAPTSLC9A1KDM4E
Water SCHEMBL6797065 0.78 KMT2A (0.32) LMNATP53MAPTSLC9A1KDM4E
SCHEMBL6798160 0.76 GAA (0.39) MCL1LMNATP53MAPTITGB3
SCHEMBL6798954 0.76 GALR3 (0.49) LMNATP53MAPTITGB3ITGA2B
SCHEMBL6798004 0.75 KMT2A (0.34) LMNATP53MAPTPHGDHSLC9A1
SCHEMBL6793054 0.74 MAPT (0.33) LMNATP53MAPTITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 MCL1 1343/4885FABP1 2553/4885LMNA 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.